BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9065922)

  • 1. Clinical efficacy of tamoxifen.
    Robert NJ
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):15-20. PubMed ID: 9065922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen's impact on the management of breast cancer: patient perspectives.
    Reichman BS
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):55-8. PubMed ID: 9065929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
    Dellapasqua S; Castiglione-Gertsch M
    Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
    Trunet P; Marty M
    Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
    Ilanchezhian S; Thangaraju M; Sachdanandam P
    Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen treatment for breast cancer: concept to gold standard.
    Jordan VC
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):7-13. PubMed ID: 9065921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The control of breast cancer: the role of tamoxifen.
    Forbes JF
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-5-S1-19. PubMed ID: 9045316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Lee JH; Recht A
    J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.